Royalty Pharma Acquires Nuvalent Royalty Interest for Up to $315 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Should l Buy NUVL?
Royalty Pharma (RPRX) announced that it has acquired a pre-existing royalty interest in Nuvalent's (NUVL) neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. Neladalkib and zidesamtinib are next-generation tyrosine kinase inhibitors. Neladalkib is in development for patients with ALK mutation-positive non-small cell lung cancer, NSCLC, and zidesamtinib is in development for ROS1 mutation-positive NSCLC. Both therapies are designed to deliver a best-in-class combination of efficacy and tolerability. Royalty Pharma is acquiring a low-single digit pre-existing royalty on worldwide net sales on each of Nuvalent's neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. The expected royalty duration for both therapies extends through approximately 2041 to 2042.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUVL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUVL
Wall Street analysts forecast NUVL stock price to rise
16 Analyst Rating
16 Buy
0 Hold
0 Sell
Strong Buy
Current: 104.530
Low
125.00
Averages
140.86
High
158.00
Current: 104.530
Low
125.00
Averages
140.86
High
158.00
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nuvalent Reports Q4 Earnings Miss with EPS of -$1.58
- Earnings Miss: Nuvalent's Q4 GAAP EPS of -$1.58 fell short of expectations by $0.09, indicating challenges in profitability that could impact investor confidence.
- Strong Cash Reserves: As of December 31, 2025, Nuvalent reported $1.4 billion in cash, cash equivalents, and marketable securities, demonstrating solid liquidity to support operations in the near term.
- Funding Outlook: The company believes its existing cash and equivalents will be sufficient to fund operations into 2029, reflecting management's optimistic view on financial stability over the next few years, which may attract long-term investor interest.
- Industry Conference Participation: Nuvalent presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the industry and potentially paving the way for future collaborations and financing opportunities.
See More
Nuvalent Advances Drug Launch Preparations for FDA Review
- FDA Review Progress: Nuvalent is preparing for the U.S. launch of zidesamtinib for TKI-pretreated ROS1-positive NSCLC patients, with a PDUFA target action date set for September 18, 2026, which could open significant market opportunities for the company.
- NDA Submission Plans: The NDA submission for neladalkib is planned for the first half of 2026, targeting TKI-pretreated ALK-positive NSCLC patients, which will further enrich the company's product pipeline and enhance its competitive position in the market.
- Label Expansion Strategy: A submission for label expansion of zidesamtinib is planned for the second half of 2026, targeting TKI-naïve ROS1-positive NSCLC patients, which will help the company broaden its market reach and meet the needs of more patients.
- Strong Financial Position: Nuvalent anticipates a robust operating runway extending into 2029, providing strong support for drug development and market launch efforts, thereby reinforcing its leadership position in precision oncology.
See More
Commodore Capital Sells Nuvalent Shares in SEC Filing
- Share Sale Overview: Commodore Capital reported the sale of 850,000 shares of Nuvalent in its SEC filing dated February 17, 2026, with an estimated transaction value of $83.81 million, reflecting its adaptability to market dynamics.
- Asset Allocation Change: This transaction reduced Nuvalent's share of Commodore Capital's 13F AUM from 9.26% to 3.68%, indicating a reassessment of risk despite Nuvalent's solid fundamentals.
- Company Financial Performance: As of February 17, 2026, Nuvalent's stock price stood at $102.24, up 29% year-over-year, significantly outperforming the S&P 500's 13% gain, indicating market recognition of its future growth potential.
- Future Development Prospects: Nuvalent ended 2025 with approximately $1.4 billion in cash, expected to last until 2029, and the FDA has accepted its NDA for zidesamtinib for ROS1 positive non-small cell lung cancer, showcasing strong momentum in oncology treatment development.
See More
Nuvalent to Speak at Biotech Summit 2026
- Executive Participation: Nuvalent's CEO Dr. James Porter and CFO Alexandra Balcom will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026, in New York City, showcasing the company's latest advancements in cancer treatment.
- Live Webcast Arrangement: The summit will feature a live webcast available in the Investors section of Nuvalent's website, with an archived version accessible for 30 days post-event, aimed at enhancing investor awareness and understanding of the company's R&D progress.
- Focus on Precision Therapy: Nuvalent is dedicated to developing precisely targeted therapies for cancer, leveraging deep expertise in chemistry and structure-based drug design to overcome the limitations of existing treatments, particularly for ROS1, ALK, and HER2-altered non-small cell lung cancer.
- Robust Pipeline Development: The company is advancing a rich pipeline of investigational candidates addressing cancer resistance, minimizing adverse events, and improving long-term patient outcomes, demonstrating its strong potential in the biopharmaceutical sector.
See More
Nuvalent to Speak at Biotech Summit 2026
- Executive Participation: Nuvalent's CEO James Porter, Ph.D., and CFO Alexandra Balcom will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, in NYC, showcasing the company's latest advancements in cancer treatment.
- Live Webcast Available: The summit will feature a live webcast accessible in the Investors section of Nuvalent's website, archived for 30 days post-presentation, ensuring investors can obtain critical information promptly.
- Focus on Precision Therapy: Nuvalent is dedicated to developing precisely targeted therapies for cancer, leveraging deep expertise in chemistry and structure-based drug design to overcome the limitations of existing treatments and drive innovation in small molecules.
- Robust R&D Pipeline: The company is advancing investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, demonstrating its potential and competitive edge in the cancer treatment market.
See More
Nuvalent Submits NDA for Zidesamtinib, Targeting Approval by September 2026
- FDA Acceptance: The FDA has accepted Nuvalent's NDA for zidesamtinib targeting TKI-pretreated patients with ROS1-positive NSCLC, with a PDUFA date set for September 18, 2026, potentially opening significant market opportunities for the company.
- Strong Financial Position: Nuvalent ended 2025 with approximately $1.4 billion in cash and equivalents, expected to fund operations into 2029, providing robust financial backing for product launches and ongoing R&D efforts.
- Future Submissions: The company plans to submit an NDA for neladalkib in the first half of 2026, targeting ALK-positive NSCLC patients, thereby expanding its product portfolio and enhancing competitive positioning in the market.
- Key Presentation: Nuvalent will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, showcasing its latest advancements in cancer treatment and increasing visibility among investors.
See More
Nuvalent Reports Q4 Earnings Miss with EPS of -$1.58
- Earnings Miss: Nuvalent's Q4 GAAP EPS of -$1.58 fell short of expectations by $0.09, indicating challenges in profitability that could impact investor confidence.
- Strong Cash Reserves: As of December 31, 2025, Nuvalent reported $1.4 billion in cash, cash equivalents, and marketable securities, demonstrating solid liquidity to support operations in the near term.
- Funding Outlook: The company believes its existing cash and equivalents will be sufficient to fund operations into 2029, reflecting management's optimistic view on financial stability over the next few years, which may attract long-term investor interest.
- Industry Conference Participation: Nuvalent presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the industry and potentially paving the way for future collaborations and financing opportunities.
See More
Nuvalent Advances Drug Launch Preparations for FDA Review
- FDA Review Progress: Nuvalent is preparing for the U.S. launch of zidesamtinib for TKI-pretreated ROS1-positive NSCLC patients, with a PDUFA target action date set for September 18, 2026, which could open significant market opportunities for the company.
- NDA Submission Plans: The NDA submission for neladalkib is planned for the first half of 2026, targeting TKI-pretreated ALK-positive NSCLC patients, which will further enrich the company's product pipeline and enhance its competitive position in the market.
- Label Expansion Strategy: A submission for label expansion of zidesamtinib is planned for the second half of 2026, targeting TKI-naïve ROS1-positive NSCLC patients, which will help the company broaden its market reach and meet the needs of more patients.
- Strong Financial Position: Nuvalent anticipates a robust operating runway extending into 2029, providing strong support for drug development and market launch efforts, thereby reinforcing its leadership position in precision oncology.
See More
Commodore Capital Sells Nuvalent Shares in SEC Filing
- Share Sale Overview: Commodore Capital reported the sale of 850,000 shares of Nuvalent in its SEC filing dated February 17, 2026, with an estimated transaction value of $83.81 million, reflecting its adaptability to market dynamics.
- Asset Allocation Change: This transaction reduced Nuvalent's share of Commodore Capital's 13F AUM from 9.26% to 3.68%, indicating a reassessment of risk despite Nuvalent's solid fundamentals.
- Company Financial Performance: As of February 17, 2026, Nuvalent's stock price stood at $102.24, up 29% year-over-year, significantly outperforming the S&P 500's 13% gain, indicating market recognition of its future growth potential.
- Future Development Prospects: Nuvalent ended 2025 with approximately $1.4 billion in cash, expected to last until 2029, and the FDA has accepted its NDA for zidesamtinib for ROS1 positive non-small cell lung cancer, showcasing strong momentum in oncology treatment development.
See More
Nuvalent to Speak at Biotech Summit 2026
- Executive Participation: Nuvalent's CEO Dr. James Porter and CFO Alexandra Balcom will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026, in New York City, showcasing the company's latest advancements in cancer treatment.
- Live Webcast Arrangement: The summit will feature a live webcast available in the Investors section of Nuvalent's website, with an archived version accessible for 30 days post-event, aimed at enhancing investor awareness and understanding of the company's R&D progress.
- Focus on Precision Therapy: Nuvalent is dedicated to developing precisely targeted therapies for cancer, leveraging deep expertise in chemistry and structure-based drug design to overcome the limitations of existing treatments, particularly for ROS1, ALK, and HER2-altered non-small cell lung cancer.
- Robust Pipeline Development: The company is advancing a rich pipeline of investigational candidates addressing cancer resistance, minimizing adverse events, and improving long-term patient outcomes, demonstrating its strong potential in the biopharmaceutical sector.
See More
Nuvalent to Speak at Biotech Summit 2026
- Executive Participation: Nuvalent's CEO James Porter, Ph.D., and CFO Alexandra Balcom will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, in NYC, showcasing the company's latest advancements in cancer treatment.
- Live Webcast Available: The summit will feature a live webcast accessible in the Investors section of Nuvalent's website, archived for 30 days post-presentation, ensuring investors can obtain critical information promptly.
- Focus on Precision Therapy: Nuvalent is dedicated to developing precisely targeted therapies for cancer, leveraging deep expertise in chemistry and structure-based drug design to overcome the limitations of existing treatments and drive innovation in small molecules.
- Robust R&D Pipeline: The company is advancing investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, demonstrating its potential and competitive edge in the cancer treatment market.
See More
Nuvalent Submits NDA for Zidesamtinib, Targeting Approval by September 2026
- FDA Acceptance: The FDA has accepted Nuvalent's NDA for zidesamtinib targeting TKI-pretreated patients with ROS1-positive NSCLC, with a PDUFA date set for September 18, 2026, potentially opening significant market opportunities for the company.
- Strong Financial Position: Nuvalent ended 2025 with approximately $1.4 billion in cash and equivalents, expected to fund operations into 2029, providing robust financial backing for product launches and ongoing R&D efforts.
- Future Submissions: The company plans to submit an NDA for neladalkib in the first half of 2026, targeting ALK-positive NSCLC patients, thereby expanding its product portfolio and enhancing competitive positioning in the market.
- Key Presentation: Nuvalent will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, showcasing its latest advancements in cancer treatment and increasing visibility among investors.
See More
